Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function

Background:

- Insulin removes sugar from the blood to use for energy. Insulin resistance means that cells may not respond to insulin normally. It can lead to serious diseases. Researchers want to see how diet affects insulin resistance, weight, and brain chemicals related to Alzheimer s disease.

Objectives:

- To compare two forms of diet and their effects on insulin resistance and the brain.

Eligibility:

- Women ages 55 70 with insulin resistance.

Design:

• This study requires 6 clinic visits over 9 12 weeks. Participants must fast before visits.
• Visit 1, screening:
• Medical history, physical exam, and blood and urine tests.
• Participants will get a wrist device to wear for 4 days.
• Visit 2:
• Weight and waist measurement.
• Blood drawn.
• Questionnaires and thinking tests.
• Lumbar puncture. Skin will be numbed and a needle inserted between bones in the back will remove <TAB>fluid.
• Participants will drink a nutrition shake. Blood will be taken 12 times over 4 <TAB>hours through a thin tube in <TAB>the arm.
• Brain MRI. Participants will lie on a table that slides in and out of a cylinder in a strong magnetic field. <TAB>They will have a coil on their head and may do tasks.
• Participants will get advice about healthy eating and be randomly put in one of 2 groups. One group will get <TAB>nutrition shakes to drink.
• Visits 3 5:
• Weight and waist measurements, vital signs, blood draw, and questionnaires.
• Between visits, participants will get a call or email to check how they are doing.
• Visit 6: Repeat of visit 1.
• Participants will wear the wrist device for 4 more days, have a follow-up contact, then the study is finished.

Study Overview

• Status: Completed
• Conditions: Obesity; Diabetes Mellitus; Alzheimer's Disease
• Intervention / Treatment: Other: Boost (R) 5-2 diet; Other: Healthy Living Diet

Detailed Description

Being overweight or obese can cause insulin resistance (IR), which is defined as reduced responsiveness to insulin by the cells of various tissues or organs. IR at midlife increases the risk of developing Alzheimer s disease (AD). We recently discovered novel biomarkers of brain IR (altered Tyr and Ser phosphorylated forms of insulin receptor substrate 1; IRS-1) in plasma exosomes enriched for neuronal origin. Moreover, IR is associated with AD biomarkers including deficits in resting state brain activity and cognitive performance. Calorie restriction is defined as consuming fewer calories than what is considered normal without a lack of nutrients. A certain type of calorie restriction, in which one consumes 500-600 calories a day for two consecutive days, followed by non-restricted eating for 5 days (5-2 CR), has been shown to lower peripheral insulin resistance effectively. Effects of CR and lowering peripheral IR on brain IR and cognition are unknown. The goal of this exploratory pilot study is to provide proof-of-concept that 5-2 CR at midlife can reverse brain IR, lower peripheral IR, improve cognitive performance, and increase brain activation at rest and during tasks. Specifically, we will study the effects of 8 weeks of 5-2 CR versus a control dietary intervention on brain and peripheral IR, memory and executive function, resting state default mode network activity, brain metabolism, and AD biomarkers. Forty overweight to obese women and men (between 55 and 70 years of age) will be randomized 1:1 into 5-2 CR and control groups. In the 5-2 CR group, participants will be offered healthy living dietary counseling at baseline, which they will be instructed to implement for five days/week. For each of the other two consecutive days/week, they will consume two shakes (Boost , CWI Medical), providing a total of 480 Kcal/day. In the control group, participants will be offered healthy living dietary counseling at baseline, which they will be asked to implement for every day of the week. Participants will undergo screening including a history and physical examination, calculation of Body Mass Index (BMI, which must be greater than or equal to 27) and a blood draw for insulin and glucose to determine whether they have insulin resistance. If participants meet eligibility criteria, they will continue with a baseline visit involving anthropometric measures, questionnaires, tests of cognitive function, brain MRI, blood draws for plasma and peripheral blood mononuclear cells, and lumbar puncture for cerebrospinal fluid biomarkers of AD. After 8 weeks, we will collect the same measures. To assess and reinforce compliance with their respective diet, participants will come into the clinic every 2 weeks to discuss compliance, measure their body weight and perform blood draws for measurement of ketones to objectively confirm energy restriction for the 5-2 CR group. We will also contact participants every week to further ensure compliance. To assess the effects of the diets on physical activity, participants will be asked to wear an accelerometer for 96 hours before and after they are on the diet.

• Study Type: Interventional
• Enrollment (Actual): 129
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21224
      • National Institute of Aging, Clinical Research Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

• INCLUSION CRITERIA:
• BMI greater than or equal to 27; in addition, weight less than or equal to 350 lbs (weight limit for MRI scanner);
• Age of 55-70 years;
• HOMA-IR greater than or equal to 1.8;
• MMSE greater than or equal to 26

EXCLUSION CRITEIRA:

• History of clinically significant cardiovascular disease for the purpose of this study, such as chronic heart failure, coronary disease, cardiomyopathy, clinically significant cardiac valvular disease or clinically significant peripheral vascular disease. Cardiovascular conditions that are clinically non-significant for the purpose of this study, such as controlled hypertension, minor EKG abnormalities, mitral valve prolapse or benign murmurs are permissible;
• History of clinically significant stroke or other neurological disease of the central nervous system;
• History of substance abuse in the past 6 months or positive urine drug screen;
• History of clinically significant endocrine disorders (common mild endocrine disorders, such as untreated subclinical hypothyroidism with TSH < 10 mU/l or successfully treated hypothyroidism may be allowed);
• History of eating disorders, significant GI disorders or malabsorption disorders;
• History of type 2 diabetes; and/or use of anti-diabetes medications or insulin; and/or type 2 diabetes diagnosed during the screening visit based on fasting glucose > 125 mg/dL;
• History of hypoglycemia; and/or a fasting glucose < 70 mg/dL during the screening visit.
• Current use of systemic corticosteroids;
• Positive screening tests for HIV, HCV or HBV;
• Hematocrit less than 35% or hemoglobin less than 11 mg/dL;
• ALT or AST > 1.5 times the upper normal limit;
• Contraindications for MRI (pacemakers, ferrous metal implants or shrapnel in or around the head, etc.).
• Contraindications to LP, such as Coumadin, coagulopathy (international normalized ratio, or INR > 1.5; prothrombin time (PT), partial prothrombin time (PTT) > 1.5 x upper normal limit). Aspirin 81 mg qd is allowed. Aspirin up to 325 mg qd is allowed, if withheld for 7 days prior to the LP.
• Pregnancy or nursing.
• Refusal to consent to genetic testing for APOE.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Healthy Living Diet; Healthy living diet for 7 days/week	Other: Healthy Living Diet; Counseling and educational material on diet portion, consistency
Experimental: 5-2 CR; Healthy living diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week.	Other: Boost (R) 5-2 diet; Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.; Other Names: 5-2 Intermittent Fasting (IF)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated Serine312-insulin Receptor Substrate-1 (pS312-IRS-1)	IRS-1 is an intracellular adaptor molecule that is being recruited and activated by the binding of insulin and insulin-like growth factor to their respective receptors and in insulin resistance (IR) it shows aberrant phosphorylation in serine residues resulting in impaired downstream signal propagation. pS312-IRS-1 is considered an index of brain insulin resistance and a therapeutic response biomarker for interventions targeting brain IR. A decrease in its levels indicates target engagement with the intervention and improvement in brain IR.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) P-pan-Tyrosine-IRS-1 (pY-IRS-1)	IRS-1 is an intracellular adaptor molecule that is being recruited and activated by the binding of insulin and insulin-like growth factor to their respective receptors and in insulin resistance (IR) it shows aberrant phosphorylation in tyrosine residues resulting in impaired downstream signal propagation. pY-IRS-1 is considered an index of brain insulin resistance and a therapeutic response biomarker for interventions targeting brain IR. A decrease in its levels indicates target engagement with the intervention and improvement in brain IR.	Week 0, Week 4, Week 8

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Change in Body Weight		Week 0, Week 8
Mean Change in Body Mass Index (BMI)		Week 0, Week 8
Mean Change in Waist Circumference		Week 0, Week 8
Mean Change in Fasting Glucose		Week 0, Week 8
Mean Change in Fasting Insulin		Week 0, Week 8
Mean Change in Homeostatic Model Assessment of Insulin Resistance 2 (HOMA2-IR)	Homeostatic Model Assessment of Insulin Resistance Index 2 (HOMA2-IR) is a marker of peripheral insulin resistance and is calculated by fasting insulin (μIU/L) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance. A cut-off of 1.8 was used to indicate peripheral insulin resistance.	Week 0, Week 8
Mean Change in Glycosylated Hemoglobin (HbA1c)		Week 0, Week 8
Mean Change in White Blood Cells (WBCs)		Week 0, Week 8
Mean Change in Red Blood Cells (RBCs)		Week 0, Week 8
Mean Change in Platelets		Week 0, Week 8
Mean Change in Hemoglobin		Week 0, Week 8
Mean Change in Hematocrit		Week 0, Week 8
Mean Change in International Normalized Ratio (INR)	The International Normalized Ratio (INR) is derived from prothrombin time (PT) which is calculated as a ratio of the patient's PT to a control PT standardized for the potency of the thromboplastin reagent developed by the World Health Organization (WHO) using the following formula: INR = Patient PT ÷ Control PT. The higher the INR, the longer it takes for blood to clot.	Week 0, Week 8
Mean Change in Serum Beta-Hydroxybutyrate (bHB)		Week 0, Week 8
Mean Change in Serum Acetoacetate (AcAc)		Week 0, Week 8
Mean Change in Serum Non-Esterified Fatty Acids (NEFA)		Week 0, Week 8
Mean Change in Serum Cortisol		Week 0, Week 8
Mean Change in Creatinine		Week 0, Week 8
Mean Change in Blood Urea Nitrogen (BUN)		Week 0, Week 8
Mean Change in Alanine Aminotransferase (ALT)		Week 0, Week 8
Mean Change in Aspartate Aminotransferase (AST)		Week 0, Week 8
Mean Change in Total Cholesterol		Week 0, Week 8
Mean Change in HDL Cholesterol		Week 0, Week 8
Mean Change in LDL Cholesterol		Week 0, Week 8
Mean Change in Triglycerides		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Amyloid Beta 42		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Amyloid Beta 40		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Amyloid Beta 42 / Amyloid Beta 40 Ratio		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Total Tau		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) p181-Tau		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Neurogranin		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Light Chain Neurofilaments (Nf-L)		Week 0, Week 8
Mean Change in Cerebrospinal Fluid (CSF) Glial Fibrillary Acidic Protein (GFAP)		Week 0, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Amyloid Beta 42		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Amyloid Beta 40		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Amyloid Beta 42 / Amyloid Beta 40 Ratio		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Total Tau		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) p181-Tau		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) p231-Tau		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Akt	Akt (or protein kinase B) is an insulin signaling cascade mediator. An increase in its levels indicates an improvement in brain insulin resistance.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated Serine473-Akt (pS473-Akt)	pS473-Akt is an insulin signaling cascade mediator. An increase in its levels indicates activation of downstream insulin signaling pathway.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated Serine473-Akt (pS473-Akt) / Akt Ratio		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated Extracellular Signal-regulated Kinase 1/2 (pERK1/2)	pERK1/2 is an insulin signaling cascade mediator. An increase in its levels indicates activation of downstream insulin signaling pathway.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated c-Jun N-terminal Kinase (pJNK)	JNK is an insulin signaling cascade mediator. Activated JNK (pJNK) inhibits insulin signaling. An increase in pJNK levels indicates inhibition of downstream insulin signaling pathway.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Phosphorylated p38 (pp38)	p38 is an insulin signaling cascade mediator. Activated p38 (pp38) inhibits insulin signaling. An increase in pp38 levels indicates inhibition of downstream insulin signaling pathway.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) proBDNF		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) BDNF		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Neurogranin		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Heavy Chain Neurofilaments (Nf-H)		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) A-synuclein		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) TAR DNA-binding Protein 43 (TDP-43)		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Monocarboxylate Transporter 1 (MCT1)		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Monocarboxylate Transporter 2 (MCT2)		Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Mitochondrial Complex IV Quantity	Complex IV is part of the mitochondrial electron transport chain. Decreased complex IV levels in NDEVs have been found in patients with Alzheimer's disease. A decrease in its levels may indicate decreased ability of neurons for ATP production and energy crisis.	Week 0, Week 4, Week 8
Mean Change in Neuron-Derived Extracellular Vesicle (NDEV) Mitochondrial Complex V Quantity	Complex V is part of the mitochondrial electron transport chain. Decreased complex V levels in NDEVs have been found in patients with Alzheimer's disease. A decrease in its levels may indicate decreased ability of neurons for ATP production and energy crisis.	Week 0, Week 4, Week 8
Mean Change in Glucose by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glucose concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glucose relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in N-acetyl-aspartate by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) N-acetyl-aspartate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. N-acetyl-aspartate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Lactate by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Lactate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Lactate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutamate by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutamate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutamate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Gamma-Aminobutyric Acid (GABA) by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Gamma-Aminobutyric Acid (GABA) concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Gamma-Aminobutyric Acid (GABA) relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutamine by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutamine concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutamine relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutathione by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutathione concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutathione relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Myo-Inositol by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Myo-Inositol concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Myo-Inositol relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in N-acetyl-aspartyl-glutamate by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) N-acetyl-aspartyl-glutamate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. N-acetyl-aspartyl-glutamate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Ascorbate by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Ascorbate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Ascorbate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Alanine by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Alanine concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Alanine relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Scyllo-Inositol by Proton J-PRESS MRS of Posteromedial Cortex (PMC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Scyllo-Inositol concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Scyllo-Inositol relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glucose by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glucose concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glucose relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Lactate by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Lactate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Lactate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutamate by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutamate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutamate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutamine by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutamine concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutamine relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Glutathione by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Glutathione concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glutathione relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Myo-Inositol by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Myo-Inositol concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Myo-Inositol relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in N-acetyl-aspartyl-glutamate by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) N-acetyl-aspartyl-glutamate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. N-acetyl-aspartyl-glutamate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Ascorbate by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Ascorbate concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Ascorbate relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Alanine by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) Alanine concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Alanine relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Scyllo-Inositol by Proton J-PRESS MRS of Medial Prefrontal Cortex (MPFC)	Proton J-PRESS Magnetic Resonance Spectroscopy (MRS) glucose concentrations were determined using the Prior-Knowledge Fitting Procedure (ProFit), which fits linear combinations of simulated two-dimensional basis metabolite spectra. Glucose relative ratio to creatine was quantified.	Week 0, Week 8
Mean Change in Executive Function Composite	Executive function was assessed with the National Institutes of Health (NIH) Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) battery that comprises written, verbal, and computerized tasks that test working memory, inhibition, set shifting, fluency, planning, insight, and social cognition and behavior. The Executive function Composite is a computerized score calculated based on the individual tests. It ranges between 0 and 10. Higher score values indicate better performance.	Week 0, Week 8
Mean Change in California Verbal Learning Test (CVLT)	California Verbal Learning Test (CVLT) assesses verbal memory for unstructured information. Examinees are asked to recall words on a 16-item list after each of 5 learning trials (Immediate Free Recall; range 0-80 [5 x 0-16]). After a distractor list, participants are again asked to recall words spontaneously (Short Delay Free Recall; range 0-16) and with category cueing (Short Delay Cued Recall; range 0-16). Spontaneous recall (Long Delay Free Recall; range 0-16) and category cueing (Long Delay Cued Recall; range 0-16) are repeated after a 20-minute delay. Following the longer delay, participants also complete a yes/no recognition trial during which they need to discriminate between the target words and 32 distractor words (Long Delay Recognition; range 0-48 [0-16 true positive target words + 0-32 true negative distractor words]). Higher scores indicate better performance.	Week 0, Week 8
Mean Change in Logical Memory (LM) Test	Logical Memory (LM) test assesses verbal memory for structured information. It consists of two thematically independent narrative stories. Each story has 25 items, which the examinee has to recall with as much detail and precision as possible. Each item is scored the same regardless of importance level, and all correct items are summed giving a maximum score of 25 for each story. "Verbatim recall" score only includes the items that are recalled exactly and with detailed information, whereas "gist recall" score includes both the verbatim recall and the items that are recalled with only the essential elements of the information. The examinee has to recall the two stories twice, immediately after their initial administration (immediate recall) and after a 20 to 30-minute delay (delayed recall). Total maximum score for each of the subtests is 50 (25 items x 2 stories) and the minimum score is 0. Higher scores indicate better performance.	Week 0, Week 8
Change in the Positive and Negative Affect Schedule (PANAS)	Positive and Negative Affect Schedule (PANAS) is a 20-item self-report measure to assess positive and negative affect and is an index of emotional state. For positive affect, score can range from 10 - 50, with higher scores representing higher levels of positive affect. For negative affect, score can range from 10 - 50, with lower scores representing lower levels of negative affect.	Week 0, Week 8
Mean Change in the Short Form 36-item Health Survey (SF-36)	Short Form 36-item Health Survey (SF-36) is a gauge of physical and psychosocial effects of the interventions. It consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability; the higher the score the less disability.	Week 0, Week 8
Mean Change in Total Energy Expenditure	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Daily Energy Expenditure	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Hourly Energy Expenditure	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Metabolic Rate	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Time in Activity	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Total Steps	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Steps Per Minute	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8
Mean Change in Total Sedentary Bouts	Physical activity was monitored with an Actigraph GT3X-BT accelerometer device which measures accelerations in vertical, horizontal, and anterior-posterior directions.	Week 0, Week 8

Collaborators and Investigators

• Sponsor: National Institute on Aging (NIA)
• Investigators: Principal Investigator: Dimitrios I Kapogiannis, M.D., National Institute on Aging (NIA)

Publications and helpful links

Helpful Links

• NIH Clinical Center Detailed Web Page

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2015
• Primary Completion (Actual): January 14, 2022
• Study Completion (Actual): December 23, 2022

Study Registration Dates

• First Submitted: May 30, 2015
• First Submitted That Met QC Criteria: May 30, 2015
• First Posted (Estimated): June 2, 2015

Study Record Updates

• Last Update Posted (Actual): April 2, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: November 15, 2023

More Information

Terms related to this study

• Keywords: Diabetes; Obesity; Biomarkers; Functional Magnetic Resonance Imaging (fMRI); Dementia of the Alzheimer Type
• Additional Relevant MeSH Terms: Mental Disorders; Glucose Metabolism Disorders; Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Hyperinsulinism; Dementia; Tauopathies; Alzheimer Disease; Insulin Resistance
• Other Study ID Numbers: 150123; 15-AG-0123

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: .There is ongoing discussion within the NIA IRP and a plan has not been finalized yet.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No